The rise of multi-receptor agonists in metabolic research has sparked a new era of peptide-based therapies targeting obesity, diabetes, and related metabolic disorders. Among these breakthroughs, two ...

Eli Lilly (LLY 0.80%) is one of the pharmaceutical industry's biggest success stories of the past several years. During the 18-month period from the end of 2022 through the end of June 2024, its stock ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Youths receiving tirzepatide had a 2.28 percentage point ...

Dr. Angela Fitch, co-founder and chief medical officer of knownwell, a "weight-inclusive" healthcare company based in Boston, said she would caution against labeling any medication as an "everything ...

NEW ORLEANS — Many of us who have tried to lose weight have been told we're just not trying hard enough. And for women after menopause, the newest study suggests it may be something completely out of ...

Patients with type 2 diabetes (T2D) on semaglutide or tirzepatide showed a higher incidence of nonarteritic anterior ischemic optic neuropathy and other optic nerve disorders compared to other ...

Mounjaro met the primary objective of non-inferiority vs. Trulicity with an 8% lower rate of MACE-3 events, while delivering greater reductions in A1C and weight In the trial, Mounjaro was associated ...

The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor size closely matched body weight and fat levels, suggesting fat reduction may slow ...

In a striking new study, the anti-obesity drug tirzepatide, known as Mounjaro and Zepbound, not only triggered significant weight loss in obese mice but also slashed breast cancer tumor growth. The ...